Lutetium Lu-177 for lung carcinoid tumors with somatostatin receptors
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests lutetium Lu 177 dotatate, a targeted radiation treatment, for advanced lung neuroendocrine (carcinoid) tumors that have a specific marker called somatostatin receptors. It may help shrink tumors by delivering radiation directly to cancer cells that “light up” on a special scan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your tumor must be a lung (bronchial) neuroendocrine tumor that is well- or moderately-differentiated, or typical/atypical carcinoid—not high-grade or poorly differentiated.
- Your scan must show somatostatin receptors on a DOTATATE PET scan (tumor uptake higher than background liver) within the past year (best within 6 months).
- You must have advanced or spreading disease that has grown on scans within the past 12 months, and you must have measurable tumors on CT or MRI.
- You should not have had prior peptide receptor radionuclide therapy (like Lu-177 dotatate) and must not have had an mTOR inhibitor (like everolimus) before.
- You must have adequate blood, kidney, liver, and nutrition test results and be well enough to do normal activities (ECOG 0–2).
- You must not be pregnant or nursing, and should not have certain serious infections or unstable conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether repeating a targeted radioactive treatment (177Lu-DOTATATE) works better than standard options in people with metastatic gastroenteropancreatic neuroendocrine tumors. It may help by controlling tumor growth after the first round of this therapy stops working.
This trial tests a radioactive drug called Lutetium-177 Oxodotreotide (a type of PRRT) for people with advanced neuroendocrine tumors that have already been treated with other therapies and are still growing. The drug targets somatostatin receptors on tumor cells to deliver radiation directly to the cancer.
This study looks at outcomes for adults with tumors that are advanced (can’t be fully removed or has spread) and are getting worse, where tests show somatostatin receptors. It aims to understand how treatment with lutetium-177 helps people in this situation.
This trial tests a radioactive drug called Lutathera for people with neuroendocrine tumors that are not in the stomach or intestines and can't be removed by surgery. The drug targets a specific receptor on the tumor cells to deliver radiation directly, which may help slow or shrink the cancer.
This Phase 2 study tests whether a radioactive medicine called lutetium Lu 177 dotatate is safe and effective for metastatic prostate cancer that has neuroendocrine features. It also checks whether patients’ scans show the cancer absorbs the drug (a requirement to start treatment).
This Phase 3 trial tests lutetium (Lu-177) oxodotreotide, a targeted treatment, for people with advanced gut and pancreas neuroendocrine tumors that are low or medium grade (G1 or G2). The study will see whether it helps control the cancer and symptoms in the right patients.
Hear when a new Lung Neuroendocrine Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.